Reproductive toxicity of ovulation induction.
The development of ovulation-inducing drugs has enabled clinicians to more effectively treat the hypothalamic, pituitary, and ovarian abnormalities resulting in infertility. Pregnancy rates have been improved with the use of agents such as clomiphene citrate (CC), human menopausal gonadotropin [hMG or follicle-stimulating hormone (FSH) preparations], with gonadotropin-releasing hormone (GnRH) and its analogs, stimulating the development of multiple ovarian follicles and increasing the number of fertilizable oocytes. The use of these drugs is not without certain detrimental or "toxic" consequences. The negative effects from superovulation can occur during follicle development, decreasing the number of healthy oocytes and embryos capable of leading to viable pregnancy. Ovulation induction can lead not only to higher incidences of spontaneous abortions, and multiple and ectopic pregnancies, but also to poor pregnancy rates, due, in part, to asynchrony between embryonic development and the uterine environment. Diseases such as ovarian hyperstimulation syndrome (OHSS), resulting in the secretion of supraphysiologic levels of estradiol, can lend to severe health complications, possibly requiring hospitalization. Most drugs used for ovulation induction can lead to OHSS. Although incidences of OHSS following CC use are less frequent, CC has been associated with hot flushes, multiple gestations, visual disturbances, cervical mucus abnormalities, and luteal phase deficiency. Finally, there are reports that link any or all of the ovulation-inducing drugs with a higher incidence of ovarian and breast cancer, however, a cause-effect relationship has yet to be proven.
Tucker
K E
KE
Department of Obstetrics and Gynecology, University of Colorado Health Sciences Center, Denver, USA.
D004717:Endometrium / Q000187:drug effects; D004958:Estradiol / Q000494:pharmacology / Q000502:physiology; D005260:Female; D005300:Fertility Agents, Female / Q000009:adverse effects*; D006801:Humans; D007247:Infertility, Female / Q000503:physiopathology / Q000628:therapy; D007986:Luteinizing Hormone / Q000097:blood; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced; D010060:Ovulation / Q000502:physiology; D010062:Ovulation Induction / Q000009:adverse effects*; D011247:Pregnancy; D011248:Pregnancy Complications
D005300:Fertility Agents, Female; D004958:Estradiol; D007986:Luteinizing Hormone